Waters Corporation and Princeton University Announce Multi-Year Research Collaboration
Agreement to take on real-world challenges in biologics and materials research
Advertisement
Waters Corporation announced a multi-year research collaboration with Princeton University that will enable scientists, faculty, and students to work together to bring their diverse skills and backgrounds to solve complex challenges in biochemistry and materials science.
Dr. Udit Batra, President and CEO of Waters Corporation, visited Princeton’s campus to discuss the collaboration with Princeton research leadership and faculty. In addition to Craig Arnold, Batra met with Clifford Brangwynne, Director of the Princeton Bioengineering Initiative and the June K. Wu '92 Professor of Engineering. Shown in the photo are Dr. Udit Batra, Waters Corporation, and Professor Craig Arnold, Princeton University. Photo Credit: Phil McAuliffe, courtesy of Princeton University.
Waters Corporation
"Solving the biggest challenges in science takes collaborations that bring together diversity of thought and expertise. Our partnership with Princeton University seeks to enable powerful research in biochemical and advanced materials engineering," said Dr. Udit Batra, President and CEO, Waters Corporation. "Together our initial work will focus on improving LC-MS workflows and sample preparation to enable our customers to conduct simpler and faster analyses with even greater precision. In turn, this will help biopharma scientists deliver therapeutics that are safe and highly effective for the treatment of disease, such as oncology and autoimmune diseases."
"As a leading global institution of research and teaching, Princeton welcomes collaborations with industry to enrich education and accelerate research and innovation for societal benefit," said Craig Arnold, Princeton University Vice Dean for Innovation and the Susan Dod Brown Professor of Mechanical and Aerospace Engineering. "We involved many Princeton faculty in our conversations with Waters as we considered this new relationship, and we were delighted to identify numerous initial research topics of mutual interest that build on Princeton's research strengths in bioengineering and materials science and the distinctive capabilities of the Princeton Bioengineering Initiative (PBI). We believe our research collaborations will advance science, as well as offer new opportunities to our faculty and students."
Under the new agreement, the Waters-Princeton collaboration will bring together academic and industry researchers to tap into knowledge and expertise from various scientific domains and disciplines to identify and solve problems that matter. One such research project will focus on novel media for purification to help advance drug development and discovery.
Other news from the department research and development
Most read news
More news from our other portals
See the theme worlds for related content
Topic World Mass Spectrometry
Mass spectrometry enables us to detect and identify molecules and reveal their structure. Whether in chemistry, biochemistry or forensics - mass spectrometry opens up unexpected insights into the composition of our world. Immerse yourself in the fascinating world of mass spectrometry!
Topic World Mass Spectrometry
Mass spectrometry enables us to detect and identify molecules and reveal their structure. Whether in chemistry, biochemistry or forensics - mass spectrometry opens up unexpected insights into the composition of our world. Immerse yourself in the fascinating world of mass spectrometry!
Last viewed contents
New biotech venture PHIOGEN to tackle the global threat of antimicrobial resistance - By optimizing nature’s defenders, the team has produced unprecedented phage treatments
CureVac and MD Anderson enter strategic collaboration to develop novel cancer vaccines - Collaboration aims to develop novel, off-the-shelf, mRNA-based cancer vaccines in selected hematological and solid cancers with high unmet medical need
CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected Glioblastoma - First patient administered in dose-confirmation Part B of Phase 1 study with mRNA-based, multiepitope cancer vaccine candidate CVGBM
First-of-its-kind vaccine expands malaria protection for pregnant women - Sanaria® PfSPZ Vaccine protects women against malaria before and during pregnancy for at least two years
Siegfried opens new global R&D Center for Drug Substances in Evionnaz - New facility to drive development excellence and further growth
QUANTRO Therapeutics achieves breakthrough in transcriptomic drug discovery - First successful simultaneous 10-target multiplex-screening
BioMed X Institute launches new cancer collaboration with Daiichi Sankyo - Call for proposals from researchers around the world to take part in this ambitious project
CureVac enters clinical phase with mRNA vaccine - First data expected on intramuscular application of the newly developed vaccine
New drug candidates reverse drug resistance in multiple myeloma in preclinical models
Elevated hormone flags liver problems in mice with methylmalonic acidemia - Study findings can immediately be applied to human patients with the disease
Investigational monoclonal antibody to treat Ebola is safe in adults
